Dinesh Thakur's guest appearances

Dinesh Thakur

Finding Genius Podcast

The Sandip Roy Show

FutureTech Podcast

From the bookshelves of Forbes India

Jeffrey M. Karp

Kenneth Witwer

Jake Steiner

Oscar Sierra

Jacopo Buongiorno

Louis Rosenberg

Christian Regenbrecht

Jennifer Conlin

Scott Nelson

Scott Turner

Valter D. Longo

Robin Bannister

Greg Lowry

Sean Buchanan

Trisha Pritikin

OwlTail

How safe are medicines made in India? Four cough and cold syrups made in India have allegedly caused the death of 66 children in the African nation of Gambia, which the Indian drug regulator is currently investigating. The syrups contained diethylene glycol (DEG) and ethylene glycol, which can be fatal for humans who consume it. India has had a record of at least five major events of poisoning by DEG in the past. In today's episode, Dinesh Thakur and Prashant Reddy, authors of The Truth Pill (published by Simon &amp; Schuster India), speak with Divya Shekhar about the problem with drug regulation in India, how drug regulators are more responsive to pharma companies rather than the people of India, and what adverse events due to substandard drugs mean for the $42 billion pharmaceutical industry in India, which, according to the Economic Survey 2021, is expected to reach $120-$130 million by 2030.

How safe are medicines made in India? Four cough and cold syrups made in India have allegedly caused the death of 66 children in the African nation of Gambia, which the Indian drug regulator is currently investigating. The syrups contained diethylene glycol (DEG) and ethylene glycol, which can be fatal for humans who consume it. India has had a record of at least five major events of poisoning by DEG in the past. In today's episode, Dinesh Thakur and Prashant Reddy, authors of The Truth Pill (published by Simon &amp; Schuster India), speak with Divya Shekhar about the problem with drug regulation in India, how drug regulators are more responsive to pharma companies rather than the people of India, and what adverse events due to substandard drugs mean for the $42 billion pharmaceutical industry in India, which, according to the Economic Survey 2021, is expected to reach $120-$130 million by 2030.

Can we trust India's drug regulator? Dinesh Thakur and Prashant Reddy weigh in

After time on the job with an Indian generic drug company, Dinesh Thankur found they were falsifying data and making subpar drugs. Here, he tells what happened next and explains:  Why there is nothing to prevent these companies from making such spurious drugs. Why the Pharmacy Benefit Manager role in the United States is key to this dangerous pattern. What are examples of actions citizens might engage in to make seemingly minor yet majorly significant changes.  Mr. Thakur was hired by an Indian generic drug company because of his expertise in the pharmaceutical and business field. However, as his work progressed, he found out that this company was manufacturing data in addition to subpar generic drug products. He made clear his objections, left, and worked with the US FDA over eight years to stop this company. In this discussion, he describes his next steps to help the prosecution and elaborates on the dangerous void in pharmaceutical quality assurance for the oversea production of generic drugs. Journalist Katherine Eban's discussion of his story in her acclaimed book Bottle of Lies brought his battle into public view. Mr. Thakur continues to shine public light on the grave problems with pharmaceutical quality assurance, specifically overseas generic drug manufacturing. He describes the lack of oversight and inability to practice solid inspections. He lists contributing factors like Medicaid's inability to negotiate prices and how that leads to this spurious drug production. Mr. Thakur also offers actionable measures we can practice to bring about change, small actions that actually have the power to engender larger and more significant results. For more about Dinesh Thakur and his contact information, see https://dineshthakur.com/.

After time on the job with an Indian generic drug company, Dinesh Thankur found they were falsifying data and making subpar drugs. Here, he tells what happened next and explains: <ul> <li>Why there is nothing to prevent these companies from making such spurious drugs.</li> <li>Why the Pharmacy Benefit Manager role in the United States is key to this dangerous pattern.</li> <li>What are examples of actions citizens might engage in to make seemingly minor yet majorly significant changes.</li> </ul> Mr. Thakur was hired by an Indian generic drug company because of his expertise in the pharmaceutical and business field. However, as his work progressed, he found out that this company was manufacturing data in addition to subpar generic drug products. He made clear his objections, left, and worked with the US FDA over eight years to stop this company. In this discussion, he describes his next steps to help the prosecution and elaborates on the dangerous void in pharmaceutical quality assurance for the oversea production of generic drugs. Journalist Katherine Eban's discussion of his story in her acclaimed book <a href="https://www.harpercollins.com/9780062338785/bottle-of-lies/" rel="nofollow" target="_blank">Bottle of Lies</a> brought his battle into public view. Mr. Thakur continues to shine public light on the grave problems with pharmaceutical quality assurance, specifically overseas generic drug manufacturing. He describes the lack of oversight and inability to practice solid inspections. He lists contributing factors like Medicaid's inability to negotiate prices and how that leads to this spurious drug production. Mr. Thakur also offers actionable measures we can practice to bring about change, small actions that actually have the power to engender larger and more significant results. For more about Dinesh Thakur and his contact information, see <a href="https://dineshthakur.com/" rel="nofollow" target="_blank">https://dineshthakur.com/</a>.

Spurious Drugs: Dinesh Thakur

After Dinesh Thankur discovered the failings of a generic drug manufacturer in India, he's been on a campaign for change. When you listen to this discussion, you'll learn  Why overseas drug companies are able to get away with producing these spurious drugs. How the middle player in the United States generic drug market, the Pharmacy Benefit Manager, keeps the harmful system in play, dodging pharmaceutical quality assurance. What steps you can take to make small yet significant changes in our policy that might prevent these fraudulent practices.   A pharmaceutical expert, Mr. Thakur discovered a company in India that hired him was falsifying data and practicing substandard manufacturing techniques with generic drugs. He left the company and helped the US FDA put the company through criminal prosecution. In this podcast, he discusses these efforts and other problems with the lack of oversight for pharmaceutical quality assurance of generic drugs produced overseas. Featured in the book Bottle of Lies by journalist Katherine Eban, Mr. Thakur has continued his activism within the current generic drug consumption in the U.S. He discusses the holes in the system, such as difficulties in inspecting an overseas manufacturer, and how the lack of power Medicaid holds in negotiating drug prices produces further roadblocks. He offers some tenable actions the average citizen can make to prevent the manufacture of these spurious drugs and shares his expertise on how small changes could improve the potentially dangerous generic drugs in our market. For more about Dinesh Thakur and his contact information, see https://dineshthakur.com/.

After Dinesh Thankur discovered the failings of a generic drug manufacturer in India, he's been on a campaign for change. When you listen to this discussion, you'll learn <ul> <li>Why overseas drug companies are able to get away with producing these spurious drugs.</li> <li>How the middle player in the United States generic drug market, the Pharmacy Benefit Manager, keeps the harmful system in play, dodging pharmaceutical quality assurance.</li> <li>What steps you can take to make small yet significant changes in our policy that might prevent these fraudulent practices. </li> </ul> A pharmaceutical expert, Mr. Thakur discovered a company in India that hired him was falsifying data and practicing substandard manufacturing techniques with generic drugs. He left the company and helped the US FDA put the company through criminal prosecution. In this podcast, he discusses these efforts and other problems with the lack of oversight for pharmaceutical quality assurance of generic drugs produced overseas. Featured in the book <a href="https://www.harpercollins.com/9780062338785/bottle-of-lies/" rel="nofollow" target="_blank">Bottle of Lies</a> by journalist Katherine Eban, Mr. Thakur has continued his activism within the current generic drug consumption in the U.S. He discusses the holes in the system, such as difficulties in inspecting an overseas manufacturer, and how the lack of power Medicaid holds in negotiating drug prices produces further roadblocks. He offers some tenable actions the average citizen can make to prevent the manufacture of these spurious drugs and shares his expertise on how small changes could improve the potentially dangerous generic drugs in our market. For more about Dinesh Thakur and his contact information, see <a href="https://dineshthakur.com/" rel="nofollow" target="_blank">https://dineshthakur.com/</a>.

Generic Fail: Dinesh Thakur Discusses the Lack of Generic Drug Manufacturing Oversight and Actions to Take